Loading clinical trials...
Loading clinical trials...
Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Probable Alzheimer's Disease or Progressive Supranuclear Palsy Compared With Healthy Volunteers
Conditions
Interventions
[18F]MNI-958
[18F]Florbetapir
+1 more
Locations
1
United States
Molecular NeuroImaging, LLC
New Haven, Connecticut, United States
Start Date
November 29, 2016
Primary Completion Date
May 11, 2018
Completion Date
May 11, 2018
Last Updated
March 25, 2019
NCT00104325
NCT07118891
NCT07545473
NCT04570085
NCT01399385
NCT07295717
Lead Sponsor
Molecular NeuroImaging
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions